ºÐÀÚÀ¯ÀüÇнÇÇè½Ç (´Ü±¹´ëÇб³ ºÐÀÚ»ý¹°Çаú)


987   Àΰ£°ú »ýÁã À¯ÀüüÀÇ À¯»ç¼º°ú Â÷ÀÌÁ¡  À̼º¿í 2014/11/25 1986
986   Cost to Develop a Drug More Than Doubles to $2.56 Billion  À̼º¿í 2014/11/21 1177
985   ¼¼±Õ°ú ½Î¿ìµµ·Ï ÀÚ±ØÇϸé, ¹ÙÀÌ·¯½º±îÁöµµ ¹°¸®Ä¡´Â ¼¼Æ÷  À̼º¿í 2014/11/20 1544
984   Gilead wins European approval of next-generation hepatitis C drug  À̼º¿í 2014/11/20 1196
983   [¹ÙÀÌ¿ÀÅäÇÈ] Ç¥ÁØ Àΰ£ °Ô³ðÁöµµÀÇ °¸À» ¸Þ¿ö¶ó: Ç÷¡Æ¼³Ñ °Ô³ðÁöµµ ź»ý  À̼º¿í 2014/11/19 1652
982   Á¾¾ç ³»¿¡¼­ T ¼¼Æ÷ ¸é¿ª¿¡ ÇÙ½ÉÀûÀÎ Ç׿øÁ¦½Ã ¼¼Æ÷  À̼º¿í 2014/11/17 1741
981   AbbVie, Enanta drug shows potential in hep C genotype 4 patients  À̼º¿í 2014/11/15 1235
  Gilead hepatitis C drug highly effective in cirrhosis patients  À̼º¿í 2014/11/14 1101
979   »õ·Î¿î HIV/AIDS Ä¡·á¹ý °³¹ß  À̼º¿í 2014/11/14 1500
978   °£ ÀÌ½Ä È¯ÀÚµéÀÇ CÇü °£¿°À» ¿ÏÄ¡½ÃŲ »õ·Î¿î Ä¡·á¹ý  À̼º¿í 2014/11/14 1711
977   °£ ÀÌ½Ä È¯ÀÚµéÀÇ CÇü °£¿°¿¡ È¿°úÀûÀÎ º´¿ë ¿ä¹ý  À̼º¿í 2014/11/13 1639
976   J&J Wins U.S. Approval for Hepatitis C Combo With Gilead  À̼º¿í 2014/11/07 1563
975   ¿¡º¼¶ó¿¡ ´ëÇÑ ¹ÝÀÀ°ú À¯ÀüÀû ¿äÀÎ  À̼º¿í 2014/11/04 1320
974   ½ÇÇè½Ç¿¡¼­ ¸¸µç ÀΰøÀ§Àå  À̼º¿í 2014/11/04 1273
973   °Å¿ïÀ̹ÌÁö RNAÈ¿¼Ò¿Í »ý¸íÀÌ ±â¿ø  À̼º¿í 2014/11/03 1527
972   ¾î¶»°Ô º¹ÀâÇÑ »ý¸íÀº ÁøÈ­Çߴ°¡?  À̼º¿í 2014/10/31 1640
971   Àΰ£ ³ì¾Æ¿ôÀ» ¿¬±¸ÇÏ´Â À¯ÀüÇÐÀÚµé  À̼º¿í 2014/10/31 1617
970   As the RNA World Turns (Either Way, with Cross-Chiral Enzyme)  À̼º¿í 2014/10/31 1385
969   ¾ÏÀÇ ¿ì±º-¿¢¼ÒÁ»(exosome)  À̼º¿í 2014/10/29 2837
968   ÀÌ¿ôÀÇ Á¤»ó¼¼Æ÷¸¦ °¨¿°½ÃŰ´Â ¾Ï¼¼Æ÷  À̼º¿í 2014/10/27 1507

[ÀÌÀü 10°³] [1]..[11][12][13][14] 15 [16][17][18][19][20]..[64] [´ÙÀ½ 10°³]
 

Copyright 1999-2023 Zeroboard / skin by ROBIN